• About
• Links
• Contact
• Sitemap

Sitemap > Breaking Research > Cardiovascular Disorders

• Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension.
• A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design.
• Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria.
• ORP150 ameliorates ischemia/reperfusion injury from middle cerebral artery occlusion in mouse brain.
• Is diabetes an independent risk factor for mortality after myocardial infarction? The ARIC (Atherosclerosis Risk in Communities) Surveillance Study.
• Serine protease inhibitor 2A inhibits caspase-independent cell death.
• Aptamer selection for the inhibition of cell adhesion with fibronectin as target.
• Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors.
• Sodium 4-phenylbutyrate protects against cerebral ischemic injury.
• Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route.
• Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study.
• Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
• Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
• 5-HT control of ischemia-evoked glutamate efflux from human cerebrocortical slices.
• Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice.
• A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma.
• Impact of diabetes mellitus on long-term outcome after unstable angina and non-ST-segment elevation myocardial infarction treated with a very early invasive strategy.
• Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys.
• Chronic exposure to morphine produces a marked cardioprotective phenotype in aged mouse hearts.
• Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction.
• Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.
• Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling.
• Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease.
• Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
• Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
• Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
• Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis.
• Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis.
• Regulation of endotoxin-induced proinflammatory activation in human coronary artery cells: expression of functional membrane-bound CD14 by human coronary artery smooth muscle cells.
• Role of protein kinase Cdelta in endothelin-induced type I collagen expression in cardiac myofibroblasts isolated from the site of myocardial infarction.
• Induction of heme oxygenase-1 expression inhibits platelet-dependent thrombosis.
• cAMP-response element-binding protein mediates tumor necrosis factor-alpha-induced vascular smooth muscle cell migration.
• Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration.
• Rates and determinants of site-specific progression of carotid artery intima-media thickness: the carotid atherosclerosis progression study.
• (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine.
• Investigations on the pharmacology of the cardioprotective guanidine ME10092.
• Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension.
• Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
• In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects.
• Synthesis and biological evaluation of novel T-type Ca2+ channel blockers.
• Glycogen synthase kinase 3beta inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia.
• Raloxifene lowers ischaemia susceptibility by increasing nitric oxide generation in the heart of ovariectomized rats in vivo.
• Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.
• Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E.
• Efficacy of candesartan in the treatment of migraine in hypertensive patients.
• Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study.
• N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo.
• A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction.
• AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
• Mouse model of microembolic stroke and reperfusion.
• The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization.
• Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study.
• Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability.
• Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents.
• Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand.
• Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa.
• Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?
• Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.
• Mitochondrial uncoupling protein 1 expressed in the heart of transgenic mice protects against ischemic-reperfusion damage.
• Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
• Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.
• Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease.
• Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
• Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
• cAMP protects endothelial barrier functions by preventing Rac-1 inhibition.
• Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning.
• Lower limb arterial incompressibility and obstruction in rheumatoid arthritis.
• Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study.
• Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis.
• A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study.
• Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.
• Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.
• Autologous vascular smooth muscle cell-based myocardial gene therapy to induce coronary collateral growth.
• Gene transfer of extracellular superoxide dismutase improves relaxation of aorta after treatment with endotoxin.
• Are we underestimating diabetes-related lower-extremity amputation rates? Results and benefits of the first prospective study.
• Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
• MC-3 receptor and the inflammatory mechanisms activated in acute myocardial infarct.
• Use of antihypertensive agents in the management of patients with acute ischemic stroke.
• Differential expression of adenylyl cyclase subtypes in human cardiovascular system.
• Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms.
• Cytoprotective efficacy and mechanisms of the liposoluble iron chelator 2,2'-dipyridyl in the rat photothrombotic ischemic stroke model.
• Vanin-1-/- mice exhibit a glutathione-mediated tissue resistance to oxidative stress.
• Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.
• A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732].
• Experimental Peptide Identification Repository (EPIR): an integrated peptide-centric platform for validation and mining of tandem mass spectrometry data.
• Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model.
• Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism.
• In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery.
• Novel diacylglycerol kinase inhibitor selectively suppressed an U46619-induced enhancement of mouse portal vein contraction under high glucose conditions.
• Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
• Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
• Protection of transplant-induced renal ischemia-reperfusion injury with carbon monoxide.
• Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril.
• pH-triggered microparticles for peptide vaccination.
• Inhibition of PLC improves postischemic recovery in isolated rat heart.
• Small interfering RNA-induced transcriptional gene silencing in human cells.
• Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques.
• Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody.
• Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
• Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer.
• Caspase-8 and caspase-3 small interfering RNA decreases ischemia/reperfusion injury to the liver in mice.
• Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation.
• Outcomes and cost of deep venous thrombosis among patients with cancer.
• Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.
• Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
• Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events.
• Quality of life after coronary artery bypass graft: results from the POST CABG Trial.
• Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
• Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure.
• Bradycardia induces angiogenesis, increases coronary reserve, and preserves function of the postinfarcted heart.
• Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis.
• Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
• Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration.
• A vascular cell-restricted RhoGAP, p73RhoGAP, is a key regulator of angiogenesis.
• Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury.
• Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis.
• Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
• Inhibition of endothelial cell proliferation by targeting Rac1 GTPase with small interference RNA in tumor cells.
• Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy.
• Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
• Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
• Intracavernosal injection of vascular endothelial growth factor improves erectile function in aged rats.
• Inhibition of poly (ADP-ribose) polymerase and caspase-3, but not caspase-1, prevents apoptosis and improves spatial memory of rats with twice-repeated cerebral ischemia.
• Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression.
• Granulocyte-macrophage colony-stimulating factor-induced arteriogenesis reduces energy failure in hemodynamic stroke.
• Functional properties of a recombinant chimeric plasminogen activator with platelet-targeted fibrinolytic and anticoagulant potential.
• Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells.
• Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
• Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study.
• Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
• Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
• Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis.
• Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study.
• Single oral dose of geranylgeranylacetone for protection against delayed neuronal death induced by transient ischemia.
• Antagonists of stretch-activated ion channels restore contractile function in hamster dilated cardiomyopathy.
• In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo.
• Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor.
• Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors.
• Chronic inflammation and impaired coronary vasoreactivity in patients with coronary risk factors.
• Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
• Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis.
• Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
• Alpha1-antitrypsin inhibits angiogenesis and tumor growth.
• Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector.
• Endothelial cell PECAM-1 confers protection against endotoxic shock.
• High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation.
• Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection.
• Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability.
• M40403 prevents myocardial injury induced by acute hyperglycaemia in perfused rat heart.
• Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1.
• The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm.
• Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model.
• Pyridoxine as a template for the design of antiplatelet agents.
• Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke.
• Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction.
• Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients.
• Effects of edaravone on reperfusion injury in patients with acute myocardial infarction.
• Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia.
• Pharmacological evidence for a key role of voltage-gated K+ channels in the function of rat aortic smooth muscle cells.
• Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults.
• Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
• Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
• PREDICT modeling and in-silico screening for G-protein coupled receptors.
• Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.
• Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease.
• Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors.
• TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply.
• Effects of nNOS antisense in the paraventricular nucleus on blood pressure and heart rate in rats with heart failure.
• Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice.
• Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice.
• C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats.
• CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation.
• Neuroprotective effect of tacrolimus (FK506) on ischemic brain damage following permanent focal cerebral ischemia in the rat.
• Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection.
• Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
• Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome.
• Neuroprotective effects of a dual L/N-type Ca(2+) channel blocker cilnidipine in the rat focal brain ischemia model.
• Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tripeptide transporter hPEPT1: design, synthesis, stability, and biological investigations.
• Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.
• Synthesis of benzimidazole based analogues of sphingosine-1-phosphate: discovery of potent, subtype-selective S1P4 receptor agonists.
• Synthesis and vasorelaxant properties of hybrid molecules out of NO-donors and the beta-receptor blocking drug propranolol.
• A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
• Comparison of three-year outcomes after coronary stenting versus coronary artery bypass grafting in patients with multivessel coronary disease, including involvement of the left anterior descending coronary artery proximally (a subanalysis of the arterial revascularization therapies study trial).
• Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis.
• Nitric oxide-releasing aspirin derivative, NCX 4016, promotes reparative angiogenesis and prevents apoptosis and oxidative stress in a mouse model of peripheral ischemia.
• Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice.
• Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice.
• Diabetes mellitus and unstable coronary artery disease: improved clinical outcome of coronary artery stenting in an era of glycoprotein IIb/IIIa inhibitors and lipid-lowering therapy.
• Treatment with {alpha}-phenyl-N-tert-butylnitrone, a free radical-trapping agent, abrogates inflammatory cytokine gene expression during alloimmune activation in rat cardiac allografts.
• Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats.
• Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial.
• Synthesis and structure-activity relationships of phenoxypyridine derivatives as novel inhibitors of the sodium-calcium exchanger.
• The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis.
• Neutralization of the chemokine CXCL10 enhances tissue sparing and angiogenesis following spinal cord injury.
• Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
• Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
• A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
• Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.
• The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals.
• Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models.
• 4-Aryl-3-(mercapto)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle.
• Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
• Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis.
• Induction of heme oxygenase-1 is involved in anti-proliferative effects of paclitaxel on rat vascular smooth muscle cells.
• The post-ischemic administration of 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e), a novel calmodulin antagonist, prevents delayed neuronal death in gerbil hippocampus.
• Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.
• Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity.
• Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes.
• Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects.
• Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
• Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms.
• Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
• Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial.
• Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries.
• Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
• Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
• Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery.
• Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy.
• Suppression of graft coronary artery disease by a brief treatment with a selective epsilonPKC activator and a deltaPKC inhibitor in murine cardiac allografts.
• Overexpression of human copper/zinc superoxide dismutase (SOD1) suppresses ischemia-reperfusion injury and subsequent development of graft coronary artery disease in murine cardiac grafts.
• Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis.
• Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease.
• Use of beta-blockers and risk of fractures.
• Endoxin antagonist lessens myocardial ischemia reperfusion injury.
• Identification of a human heme exporter that is essential for erythropoiesis.
• JunD reduces tumor angiogenesis by protecting cells from oxidative stress.
• Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo.
• Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death.
• VIAF, a conserved inhibitor of apoptosis (IAP)-interacting factor that modulates caspase activation.
• Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.
• Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP.
• Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).
• Comparison of frequency of insulin resistance after coronary stenting in patients with type 2 diabetes mellitus with versus without coronary restenosis.
• Gene therapy for chronic myocardial ischemia using platelet-derived endothelial cell growth factor in dogs.
• Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury.
• cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling.
• Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa.
• Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
• Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
• Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
• Ximelagatran: an oral direct thrombin inhibitor.
• OX40 (CD134) blockade inhibits the co-stimulatory cascade and promotes heart allograft survival.
• Cardiovascular risk and COX-2 inhibition in rheumatological practice.
• Novel RGD-like molecules based on the tyrosine template: design, synthesis, and biological evaluation on isolated integrins alphaVbeta3/alphaIIbbeta3 and in cellular adhesion tests.
• Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
• E-selectin blockade decreases adventitial inflammation and attenuates intimal hyperplasia in rat carotid arteries after balloon injury.
• Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
• Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2.
• The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents.
• Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
• Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability.
• Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice.
• Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model.
• Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
• Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
• SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
• 5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa.
• The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.
• A protein tyrosine phosphatase inhibitor accelerates angiogenesis in a rat model of hindlimb ischemia.
• p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in rats.
• In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
• FR167653 diminishes infarct size in a murine model of myocardial ischemia-reperfusion injury.
• Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
• Mitochondrial KATP channels in hindlimb remote ischemic preconditioning of skeletal muscle against infarction.
• Effect of 3beta-hydroxysteroid dehydrogenase inhibition by trilostane on blood pressure in the Dahl salt-sensitive rat.
• Inhibition of endogenous leptin protects mice from arterial and venous thrombosis.
• Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.
• Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis.
• Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III).
• Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV.
• A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design [ISRCTN55725285].
• The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.
• High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial.
• Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
• Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension.
• Safety of rosuvastatin.
• Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study).
• Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors.
• Meta-analysis of allograft bypass grafting to infrapopliteal arteries.
• Long-term outcome following thrombembolectomy in the upper extremity.
• Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials.
• NOS3 deficiency augments hypoxic pulmonary vasoconstriction and enhances systemic oxygenation during one-lung ventilation in mice.
• p38 MAP kinase inhibitor reverses stress-induced cardiac myocyte dysfunction.
• BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
• A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.
• Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways.
• The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study.
• Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone.
• Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury.
• Estrogen plus progestin and risk of venous thrombosis.
• Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.
• [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker]
• Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis.
• [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results]
• Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure.
• VEGF receptor antagonism blocks arteriogenesis, but only partially inhibits angiogenesis, in skeletal muscle of exercise-trained rats.
• Novel therapeutic approach for cancer using four cardiovascular hormones.
• The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease.
• Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity.
• Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
• Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.
• Mechanism of cardiac depression after trauma-hemorrhage: increased cardiomyocyte IL-6 and effect of sex steroids on IL-6 regulation and cardiac function.
• betaARK1 inhibition improves survival in a mouse model of heart failure induced by myocardial infarction.
• Angiotensin receptor blockade decreases markers of vascular inflammation.
• Nitric-oxide mediated effects of transdermal capsaicin patches on the ischemic threshold in patients with stable coronary disease.
• Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study.
• In vivo protein transduction: biologically active intact pep-1-superoxide dismutase fusion protein efficiently protects against ischemic insult.
• Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats.
• Adenoviral gene transfer with soluble vascular endothelial growth factor receptors impairs angiogenesis and perfusion in a murine model of hindlimb ischemia.
• The erythropoietin-receptor pathway modulates survival of cancer cells.
• Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes.
• Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
• Nasal administration of albuterol: an alternative route of delivery.
• Structure-activity relationship studies on chalcone derivatives: potent inhibition of platelet aggregation.
• Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP.
• Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin.
• Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration.
• Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists.
• ASHP Therapeutic Position Statement on the Use of Low-Molecular-Weight Heparins for Adult Outpatient Treatment of Acute Deep-Vein Thrombosis.
• Atherosclerotic renal artery stenosis: one year outcome of total and separate kidney function following stenting.
• Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol.
• The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
• p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
• Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy.
• Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference.
• Hydrocortisone reduces restenosis after stenting of small coronary arteries.
• Double transgenic mice with type 1 diabetes mellitus develop somatic, metabolic and vascular disorders.
• Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
• Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo.
• Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor.
• Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide.
• Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2.
• Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet.
• Mixed xenogeneic chimerism induces donor-specific humoral and cellular immune tolerance for cardiac xenografts.
• Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome.
• Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
• Stroke risk and tamoxifen therapy for breast cancer.
• Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect.
• Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis.
• Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury.
• Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients.
• Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice.
• Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat.
• Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure.
• 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability.
• CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling.
• Superoxide dismutase mimetic m40401 reduces ischemia-reperfusion injury and graft coronary artery disease in rodent cardiac allografts.
• TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy.
• Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis.
• Association of protein tyrosine phosphatase 1B gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the insulin resistance atherosclerosis study (IRAS) family study.
• Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis.
• Hepatocyte growth factor suppresses vascular medial hyperplasia and matrix accumulation in advanced pulmonary hypertension of rats.
• Novel antiinflammatory vascular benefits of systemic and stent-based delivery of ethylisopropylamiloride.
• A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
• Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway.
• Effects of intracerebroventricular application of brain-derived neurotrophic factor on cerebral recovery after cardiac arrest in rats.
• NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs.
• Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo.
• The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates.
• Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.
• Small proline-rich protein 1A is a gp130 pathway- and stress-inducible cardioprotective protein.
• Inhalation of carbon monoxide prevents liver injury and inflammation following hind limb ischemia/reperfusion.
• Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis.
• Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
• Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.
• Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
• Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
• Cyclooxygenase-2 and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn pigs.
• Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
• VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
• Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times.
• Class effect of angiotensin-converting enzyme inhibitors on prevention of myocardial infarction.
• Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial.
• Myocardial protective effect of FR167653; a novel cytokine inhibitor in ischemic-reperfused rat heart.
• The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes.
• Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction.
• Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype.
• Hyperinsulinaemia is associated with increased long-term mortality following acute myocardial infarction in non-diabetic patients.
• Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative.
• Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.
• Calpain inhibitor-1 protects the rat heart from ischemia-reperfusion injury: analysis by mechanical work and energetics.
• PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.
• Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets.
• Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice.
• An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
• Galantamine blocks cloned Kv2.1, but not Kv1.5 potassium channels.
• Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis.
• Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial.
• Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic.
• Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
• Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction.
• Beyond hypertension toward guidelines for cardiovascular risk reduction.
• Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury.
• Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts.
• Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
• Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
• Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.
• AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics.
• Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin.
• HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation.
• Ligand discovery using small molecule microarrays.
• Inhibition of L-type Cav1.2 Ca2+ channels by 2,(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) and 2-[1-(3-dimethyl-aminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl) maleimide (Go6983).
• A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
• Adrenomedullin enhances therapeutic potency of bone marrow transplantation for myocardial infarction in rats.
• Antihypertensive effect of 5-HT1A agonist buspirone and 5-HT2B antagonists in experimentally induced hypertension in rats.
• Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study).
• Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia.
• Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial.
• Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
• Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity.
• Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents.
• Enhanced arteriogenesis and wound repair in dystrophin-deficient mdx mice.
• Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure.
• Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants.
• Insulin resistance as a contributor to myocardial ischaemia independent of obstructive coronary atheroma: a role for insulin sensitisation?
• Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis.
• Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress.
• BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells.
• HO-1 induction restores c-AMP-dependent lung epithelial fluid transport following severe hemorrhage in rats.
• Pharmacological effects of ATI22-107 [2-(2-{2-[2-chloro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-acetylamino}-ethoxymethyl)-4-(2-chloro-phenyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester)], a novel dual pharmacophore, on myocyte calcium cycling and contractility.
• Macrophage inhibitor, semapimod, reduces tumor necrosis factor-alpha in myocardium in a rat model of ischemic heart failure.
• Effects of SEA0400, a novel inhibitor of the Na+/Ca2+ exchanger, on myocardial stunning in anesthetized dogs.
• Preventive effect of Y-27632, a selective Rho-kinase inhibitor, on ischemia/reperfusion-induced acute renal failure in rats.
• CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule.
• Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis.
• Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy.
• Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713.
• Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart.
• Obesity and the risk of new-onset atrial fibrillation.
• Trends in cardiovascular complications of diabetes.
• Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease.
• Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion.
• Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.
• Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents.
• Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel.
• Direct-acting fibrinolytic enzymes in shark cartilage extract: potential therapeutic role in vascular disorders.
• Adenovirus-mediated intraarterial delivery of PTEN inhibits neointimal hyperplasia.
• Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
• Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
• Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study.
• Simvastatin enhances myocardial angiogenesis induced by vascular endothelial growth factor gene transfer.
• Ghrelin inhibits FGF-2-mediated angiogenesis in vitro and in vivo.
• Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.
• Artificial cell microcapsule for oral delivery of live bacterial cells for therapy: design, preparation, and in-vitro characterization.
• Reduction of myocardial infarction by calpain inhibitors A-705239 and A-705253 in isolated perfused rabbit hearts.
• Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases.
• Increased expression and altered subcellular distribution of PKC-delta in chronically hypoxic rat myocardium: involvement in cardioprotection.
• Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition.
• Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.
• High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes.
• Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction.
• 5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa.
• N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
• Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors.
• Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
• Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice.
• Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation.
• Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells.
• Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial.
• Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3.
• Effects of Y-27632, a selective Rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats.
• Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors.
• Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia.
• Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.
• Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium.
• Effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on cardiovascular alterations in endotoxemia.
• CCR4-deficient mice show prolonged graft survival in a chronic cardiac transplant rejection model.
• Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both.
• Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies.
• Synchronized infection of cell cultures by magnetically controlled virus.
• Treatment of coronary artery disease in dialysis patients with sirolimus-eluting stents: 1-year clinical follow-up of a consecutive series of cases.
• Discovery of inhibitors of MCF-7 tumor cell adhesion to endothelial cells and investigation on their mode of action.
• Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
• Trends in hypertension-related death in the United States: 1980-1998.
• Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease.
• Membrane fixation of vascular endothelial growth factor receptor 1 ligand-binding domain is important for vasculogenesis and angiogenesis in mice.
• Inflammatory markers and the risk of coronary heart disease in men and women.
• Risk of myocardial infarction and stroke after acute infection or vaccination.
• Inhibition of tumor growth in xenografted nude mice with adenovirus-mediated endostatin gene comparison with recombinant endostatin protein.
• Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonists.
• Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor.
• Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents.
• Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes.
• Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
• Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial.
• Aquaporin-2 water channels in spontaneously hypertensive rats.
• A novel class of fusion polypeptides inhibits exocytosis.
• Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing.
• Protective role of angiopoietin-1 in endotoxic shock.
• Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors.
• Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice.
• Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
• Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model.
• Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
• Smooth muscle cell expression of a constitutive active form of human Rac 1 accelerates cutaneous wound repair.
• A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
• Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI.
• Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
• Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting.
• Accurate multiplex gene synthesis from programmable DNA microchips.
• Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.
• Clinical efficacy and safety of telmisartan 80 mg once daily compared with enalapril 20 mg once daily in patients with mild-to-moderate hypertension: results of a multicentre study.
• Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension.
• Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study.
• The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension.
• Intra-arterial thrombolysis for acute ischemic stroke: preliminary experience with platelet glycoprotein IIb/IIIa inhibitors as adjunctive therapy.
• 11beta-Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension.
• The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years.
• Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells.
• Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure.
• Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial).
• The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo.
• Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques.
• MK2-/- gene knockout mouse hearts carry anti-apoptotic signal and are resistant to ischemia reperfusion injury.
• Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction.
• ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
• 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
• Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.
• Expression of the LXRalpha protein in human atherosclerotic lesions.
• Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors.
• Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction.
• Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
• A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo.
• Retinopathy and risk of congestive heart failure.
• Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials.
• Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.
• Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics.
• Thrombolytic activity of BB-10153, a thrombin-activatable plasminogen.
• Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin.
• High-throughput screening of novel peptide inhibitors of an integrin receptor from the hexapeptide library by using a protein microarray chip.
• Transcriptional-based screens for pathway-specific, high-throughput target discovery in endothelial cells.
• C-reactive protein levels and outcomes after statin therapy.
• Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
• FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers.
• Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?
• Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes.
• Recombinant adeno-associated virus vector expressing angiostatin inhibits preretinal neovascularization in adult rats.
• Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo.
• Association between hormone replacement therapy and subsequent stroke: a meta-analysis.
• Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and proliferation in human vascular endothelial cells.
• Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo.
• KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts.
• Statin use and survival outcomes in elderly patients with heart failure.
• Microalbuminuria, renal function and development of sustained hypertension: a longitudinal study in the early stage of hypertension.
• Targeting human cancer cells with VEGF receptor-2-directed liposomes.
• Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
• Local delivery of soluble TNF-alpha receptor 1 gene reduces infarct size following ischemia/reperfusion injury in rats.
• Protective effects of TASK-3 (KCNK9) and related 2P K channels during cellular stress.
• Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy.
• Protective effects of intermedin/adrenomedullin2 on ischemia/reperfusion injury in isolated rat hearts.
• HIV-based vectors and angiogenesis following rabbit hindlimb ischemia.
• Synthesis and structure-activity relationships of 6-{4-[(3-fluorobenzyl)oxy]phenoxy}nicotinamide derivatives as a novel class of NCX inhibitors: a QSAR study.
• Synthesis and structure-activity relationships of benzyloxyphenyl derivatives as a novel class of NCX inhibitors: effects on heart failure.
• In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signaling.
• Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway.
• The vascular effects of doxazosin in hypertension complicated by metabolic syndrome.
• RNA polymerase IV directs silencing of endogenous DNA.
• Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
• Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
• Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent.
• Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells.
• Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC.
• Cimetidine inhibits angiogenesis and suppresses tumor growth.
• BMS-191095, a cardioselective mitochondrial K(ATP) opener, inhibits human platelet aggregation by opening mitochondrial K(ATP) channels.
• Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.
• Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
• Discovery of a novel class of reversible non-peptide caspase inhibitors via a structure-based approach.
• Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice.
• Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice.
• Adenovirus-mediated gene transfer of heparin-binding epidermal growth factor-like growth factor enhances neurogenesis and angiogenesis after focal cerebral ischemia in rats.
• Anti-angiogenic properties of plaunotol.
• Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
• First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
• Thrombophilic risk factors in patients with severe carotid atherosclerosis.
• In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
• Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane.
• Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
• Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study.
• Imaging of tumor angiogenesis in rat brains in vivo by photoacoustic tomography.
• Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan.
• Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.
• A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
• Engineering of vault nanocapsules with enzymatic and fluorescent properties.
• Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms.
• Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
• Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction.
• Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
• Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance.
• Discovery of novel non-peptidic ketopiperazine-based renin inhibitors.
• Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
• AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.
• Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting.
• Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure.
• Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
• Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial.
• High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension.
• A study of statin use in the prevention of cognitive impairment of vascular origin in the UK.
• Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro.
• Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
• Adenoviral gene transfer of FGF-5 to hibernating myocardium improves function and stimulates myocytes to hypertrophy and reenter the cell cycle.
• Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction.
• Inhibitors of calpain activation (PD150606 and E-64) and renal ischemia-reperfusion injury.
• Functional proteins involved in regulation of intracellular Ca(2+) for drug development: pharmacology of SEA0400, a specific inhibitor of the Na(+)-Ca(2+) exchanger.
• 1,3-Dioxo-4-methyl-2,3-dihydro-1H-pyrrolo[3,4-c]quinolines as potent caspase-3 inhibitors.
• Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure.
• Comparison of cilostazol and clopidogrel after successful coronary stenting.
• Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH).
• Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
• Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats.
• Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor.
• Percutaneous endovascular treatment for chronic limb ischemia.
• The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
• YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models.
• Small interfering RNA-mediated functional silencing of vasopressin V2 receptors in the mouse kidney.
• Target-directed proteolysis at the ribosome.
• Characterization of a monoclonal antibody that antagonizes the function of human endostatin.
• Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
• Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation.
• Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials.
• PARG activity mediates intestinal injury induced by splanchnic artery occlusion and reperfusion.
• Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol.
• Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition.
• A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
• Anti-proliferating effect of iptakalim, a novel KATP channel opener, in cultured rabbit pulmonary arterial smooth muscle cells.
• Direct, pleiotropic protective effect of cyclosporin A against simulated ischemia-induced injury in isolated cardiomyocytes.
• Effects of KR-32570, a new Na+/H+ exchanger inhibitor, on functional and metabolic impairments produced by global ischemia and reperfusion in the perfused rat heart.
• Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells.
• Protein kinase C-zeta inhibition exerts cardioprotective effects in ischemia-reperfusion injury.
• Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production.
• Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt].
• BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump.
• Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention.
• Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule.
• Calmodulin kinase II inhibition protects against structural heart disease.
• Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis.
• Thrombosis modulates arterial drug distribution for drug-eluting stents.
• 2004 American College of Cardiology/American Heart Association guidelines for the management of patients with ST-elevation myocardial infarction: implications for emergency department practice.
• In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker.
• Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.
• Calcimimetic NPS R-568 induces hypotensive effect in spontaneously hypertensive rats.
• The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly.
• Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy.
• 3-Substituted imidazo[1,2-d][1,2,4]-thiadiazoles: a novel class of factor XIIIa inhibitors.
• 9-hydroxyazafluorenes and their use in thrombin inhibitors.
• Druggability indices for protein targets derived from NMR-based screening data.
• High-throughput lipophilicity measurement with immobilized artificial membranes.
• A single-centre prospective study of clinical and haemostatic risk factors for venous thromboembolism following lower limb arthroplasty.
• Regulation of endothelial cell and endothelial progenitor cell survival and vasculogenesis by integrin-linked kinase.
• Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis.
• Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer.
• FTY720 inhibits tumor growth and angiogenesis.
• A novel immunomodulator KRP-203 combined with cyclosporine prolonged graft survival and abrogated transplant vasculopathy in rat heart allografts.
• Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial.
• The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.
• Overexpression of sorcin enhances cardiac contractility in vivo and in vitro.
• Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension.
• Change in body mass index and its impact on blood pressure: a prospective population study.
• Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.
• The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure.
• Inhibition of ribonucleotide reductase reduces neointimal formation following balloon injury.
• Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction.
• Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
• Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption.
• Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis.
• Gene transfer of inhibitor kappaB in human lung cancer cell line NCI-H460 inhibits tumorigenesis and angiogenesis in vivo.
• Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production.
• Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.
• A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status.
• Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
• Lipid-lowering therapy in patients with peripheral arterial disease: are guidelines being met?
• Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction.
• A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol.
• The efficacy of a 'master switch gene' HIF-1alpha in a porcine model of chronic myocardial ischaemia.
• Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs.
• Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke.
• MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial.
• Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension.
• Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.
• Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
• A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
• Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey.
• Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
• (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1.
• Insulin resistance in men with treated hypertension at increased risk for cardiovascular disease: results of a 3-year study.
• PPARgamma in endothelial cells influences high fat diet-induced hypertension.
• Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.
• The British Cardiac Society Working Group definition of myocardial infarction: implications for practice.
• Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia.
• Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure.
• Pentoxifylline attenuates cardiac dysfunction and reduces TNF-alpha level in ischemic-reperfused heart.
• Lactadherin promotes VEGF-dependent neovascularization.
• PI 3-kinase p110beta: a new target for antithrombotic therapy.
• Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
• Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial.
• Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
• Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.
• Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor.
• Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists.
• Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
• The ATP-sensitive potassium channel blocker glibenclamide prevents renal ischemia/reperfusion injury in rats.
• Oligomycin inhibits HIF-1alpha expression in hypoxic tumor cells.
• Trimetazidine normalizes postischemic function of hypertrophied rat hearts.
• Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts.
• Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia.
• Myocardial infarction risk and tamoxifen therapy for breast cancer.
• Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure.
• Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels.
• Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis.
• Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis.
• Intra-arterial thrombolysis in acute ischaemic stroke.
• Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: the Asian Pacific Multicenter Arthos Stent Study (PASS) trial.
• Deep venous thrombosis in elderly hospitalized patients: prevalence and clinical features.
• Effect of endothelin antagonist (TAK-044) on cerebral ischemic volume, oxidative stress markers and neurobehavioral parameters in the middle cerebral artery occlusion model of stroke in rats.
• roundabout4 is essential for angiogenesis in vivo.
• Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
• Selective thromboxane A2 synthase inhibition by OKY-046 prevents cardiopulmonary dysfunction after ovine smoke inhalation injury.
• Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.
• Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
• Local overexpression of HB-EGF exacerbates remodeling following myocardial infarction by activating noncardiomyocytes.
• Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities.
• Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial.
• Risk factors for thromboembolic events in renal failure.
• Doxazosin GITS versus standard doxazosin in mild to moderate hypertension.
• Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial.
• The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
• Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
• Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis.
• Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload.
• Fluoxetine and recovery of motor function after focal ischemia in rats.
• A novel class of sodium/calcium exchanger inhibitor: design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives.
• Non-peptidic alpha(v)beta3 antagonists containing indol-1-yl propionic acids.
• Prevalence of anemia and effects on mortality in patients with heart failure.
• Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
• Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression.
• Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS).
• Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis.
• How should patients with unstable angina and non-ST-segment elevation myocardial infarction be managed? A meta-analysis of randomized trials.
• Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.
• Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure.
• Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure.
• A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.
• Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
• Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
• Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis.
• Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study.
• Impact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of aspirin.
• Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
• Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
• Adenovirus-mediated gene transfer of superoxide dismutase and catalase decreases restenosis after balloon angioplasty.
• Anti-angiogenic and anti-tumor apoptotic activities of a topoisomerase II inhibiting agent SJ-8026.
• 17 Beta-estradiol improves survival in male mice with cardiomyopathy induced by cardiac-specific tumor necrosis factor-alpha overexpression.
• Disodium Disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion.
• Cardioprotective effects of KB-R7943, a novel inhibitor of Na+/Ca2+ exchanger, on stunned myocardium in anesthetized dogs.
• Use of PROTACS as molecular probes of angiogenesis.
• Synthesis of all-trans arachidonic acid and its effect on rabbit platelet aggregation.
• Relation of the metabolic syndrome to calcified atherosclerotic plaque in the coronary arteries and aorta.
• Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.
• The evaluation of 2,8-disubstituted benzoxazinone derivatives as anti-inflammatory and anti-platelet aggregation agents.
• Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
• Cardioprotection without cardiosuppression by SEA0400, a novel inhibitor of Na+-Ca2+ exchanger, during ischemia and reperfusion in guinea-pig myocardium.
• Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003.
• Tr